NEW YORK (GenomeWeb) – Bristol-Myers Squibb has partnered with Enterome to discover and develop microbiome-derived biomarkers, drug targets, and bioactive molecules that may be used in the development of new cancer companion diagnostics and therapeutics, the companies announced today.

As part of the deal, the companies will also try to identify microbiome biomarkers that can be used to improve the clinical outcomes of patients treated with Bristol-Myers Squibb's immuno-oncology drugs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.

Nov
02
Sponsored by
Qiagen

This webinar will discuss the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Dec
05
Sponsored by
Agilent Technologies

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.